Aditya Juloori: Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Aditya Juloori, Radiation Oncologist at The University of Chicago Medical Center, shared on X:

“Check out our multi-center phase 2 IIT currently accruing for upfront SBRT added to Durvalumab-based chemoimmunotherapy for the first line treatment of extensive stage SCLC – the DARES trial.”

DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer

Authors: Christine M. Bestvina, Jared H. L. Hara, Theodore Karrison, Benjamen Bowar, Janet Chin, Marina C. Garassino, Sean P. Pitroda, Rajat Thawani, Everett E. Vokes, Gregory Gan, Jun Zhang, Andrew M. Baschnagel, Toby C. Campbell, Steven Chmura and Aditya Juloori.

Source: Aditya Juloori/X